Antimicrobial resistance surveillance of doripenem in China

Journal of Antibiotics

Volumn 68, Issue 8, 2015, Pages 496-500

  Li, Yun ^a   Lv, Yuan ^a   Xue, Feng ^a   Zheng, Bo ^a   Liu, Jian ^a   Zhang, Jia ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZITHROMYCIN; CARBAPENEM; CEFEPIME; CEFOPERAZONE; CEFOPERAZONE PLUS SULBACTAM; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CHLORAMPHENICOL; COLISTIN; COTRIMOXAZOLE; DORIPENEM; GENTAMICIN; IMIPENEM; LATAMOXEF; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHINA; CLINICAL LABORATORY; CONTROLLED STUDY; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TERTIARY CARE CENTER; BACTERIAL INFECTION; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; HOSPITAL; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PREVALENCE;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CARBAPENEMS; CHINA; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; EPIDEMIOLOGICAL MONITORING; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; PSEUDOMONAS AERUGINOSA;

EID: 84940558623     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2015.25     Document Type: Article

References (13)

1. Tsuji, M, Ishii, Y & Ohno, A. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob. Agents Chemother. 42, 94-99 (1998).
2. Zheng, X. X., Hou, G. J. & Lin, Z. M. Pharmacological characteristics and clinical application of doripenem. Evaluation and Analysis of Drug-use in Hospital of China 11, 195-197 (2011).
3. Jones, R. N., Huynh, H. K. & Biedenbach, D. J. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob. Agents Chemother. 48, 3136-3140 (2004).
4. Sahm,D. In vitro activity of doripenem. Clin. Infect. Dis. 49, S11-S16 (2009).
5. Marti, S., Sanchez-Cespedes, J., Alba, V. & Vila, J. In vitro activity of doripenem against Acinetobacter baumannii clinical isolates. Inter. J. Antimicrob. Agents 33, 181-182 (2009).
6. Li, Y. et al. Anticicrobial susceptibility surveillance in China: a MOHNARIN program report (2009-2010). Clin. J. Lab. Med. 35, 67-87 (2012).
7. Li, J.T., Li, Y. & Wang, J. Surveillance on drug resistance of gram-negative bacilli isolated from hospital acquired infections and community acquired infections (2000-2001). Natl Med. J. China 83, 1035-1045 (2003).
8. Li, J.T., Li, Y. & Qi, H. M. 2002-2003 bacterial resistance surveillance study on gram-negative bacilli in China. Chin. J. Lab. Med. 28, 19-29 (2005).
9. Li, Y., Xiao, Y. H. & Wang, J. Surveillance of gram-negative bacterial resistance: data from Ministry of Health P. R. China National Antibacterial Resistance Investigation Net in 2004-2005. Chin. J. Infect. Dis. 26, 202-210 (2008).
10. Li, Y. et al. Antimicrobial susceptibility surveillance in China: a MOHNARIN program 2007-2008 report. Chin. J. Clin. Pharmacol. 27, 323-334 (2011).
11. Li, Y. et al. Antimicrobial susceptibility surveillance of gram-negative bacteria from MOHNARIN 2011-2012. Chin. J. Clin. Pharmacol. 30, 260-277 (2014).
12. Jean, S. S. et al. In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units: nationwide data from SMART Programme. Eur. J. Clin. Microbiol. Infect. Dis. 29, 471-475 (2010).
13. Nordmann, P. et al. Comparative activity of carbapenem testing: the COMPACT study. J. Antimicrob. Chemother. 66, 1070-1078 (2011).